Versant Capital Management, Inc Celldex Therapeutics, Inc. Transaction History
Versant Capital Management, Inc
- $431 Million
- Q3 2024
A detailed history of Versant Capital Management, Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 92 shares of CLDX stock, worth $2,395. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92Holding current value
$2,395% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$241 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$122 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$101 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$90.1 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$86.8 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.22B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...